LF
VRTX icon

Lansforsakringar Fondforvaltning’s Vertex Pharmaceuticals VRTX Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.6M Sell
79,627
-4,219
-5% -$1.87M 0.18% 99
2026
Q1 		$37.4M Sell
83,846
-7,980
-9% -$3.72M 0.2% 100
2025
Q4 		$41.6M Sell
91,826
-54,737
-37% -$23.6M 0.21% 95
2025
Q3 		$57.4M Buy
146,563
+5,273
+4% +$2.2M 0.3% 63
2025
Q2 		$62.9M Buy
141,290
+4,979
+4% +$2.29M 0.36% 54
2025
Q1 		$66.1M Sell
136,311
-8,397
-6% -$3.91M 0.41% 47
2024
Q4 		$58.3M Buy
+144,708
New +$67.1M 0.33% 59

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Lansforsakringar Fondforvaltning's VRTX Position: Q2 2026 in Review

Lansforsakringar Fondforvaltning reduced its Vertex Pharmaceuticals (VRTX) stake by 5% in Q2 2026, selling an estimated $1.87M and leaving 79,627 shares worth $39.6M. The position accounts for 0.18% of the portfolio, ranked #99.

Lansforsakringar Fondforvaltning first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $66.1M in Q1 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Lansforsakringar Fondforvaltning held 79,627 shares of Vertex Pharmaceuticals worth $39.6M as of Q2 2026.
  • Lansforsakringar Fondforvaltning sold 4,219 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.87M.
  • Vertex Pharmaceuticals made up 0.18% of Lansforsakringar Fondforvaltning's portfolio in Q2 2026, its #99 holding.
  • Lansforsakringar Fondforvaltning first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Lansforsakringar Fondforvaltning's Vertex Pharmaceuticals position peaked at $66.1M in Q1 2025.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q2 2026, filed 13 Aug 2026.